Immunotherapy and Cancer Therapeutics: A Rich Partnership

Gang Chen, Elizabeth M. Jaffee, Leisha A. Emens

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Cancer is managed by surgery, radiation therapy, and systemic drug therapies. Drug therapies include endocrine manipulation, single- or multi-agent chemotherapy, and monoclonal antibody therapy. Targeted small molecules that specifically capitalize on vulnerabilities that map to signaling pathways indispensible for tumor growth and progression are now also a part of the standard of cancer care. More recently, rapidly accumulating data illustrates a critical role for the immune system in the response to chemotherapy, radiation (the abscopal effect), and novel targeted cancer therapies. Integrating immune-based therapies strategically with established and novel cancer therapeutics should generate a robust antitumor effect that takes advantage of the strengths of their individual modes of action and also leverages potential immunologic synergies.

Original languageEnglish (US)
Title of host publicationCancer Immunotherapy
Subtitle of host publicationImmune Suppression and Tumor Growth: Second Edition
PublisherElsevier Inc.
Pages415-432
Number of pages18
ISBN (Print)9780123942968
DOIs
StatePublished - Jul 2013

    Fingerprint

Keywords

  • Cancer therapeutics
  • Chemotherapy
  • Immunotherapy
  • Monoclonal antibodies
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Medicine(all)
  • Dentistry(all)

Cite this

Chen, G., Jaffee, E. M., & Emens, L. A. (2013). Immunotherapy and Cancer Therapeutics: A Rich Partnership. In Cancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition (pp. 415-432). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-394296-8.00025-7